Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA970A + Montanide + Durvalumab in HCC
NCT06218511Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMA970A in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 55 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
IMA970A
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06218511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218511.